Sacubitril/Valsartan

Montreal, Quebec – November 19, 2025 – Thryv Therapeutics Inc., a clinical-stage biotechnology company advancing a series of novel serum glucocorticoid inducible kinase 1 (SGK1) inhibitors for inherited cardiac arrhythmias, cardiometabolic diseases, and cardiomyopathies, today announced that new preclinical data will be presented at the American Heart Association’s Scientific Sessions 2025, taking place November 8–10 in New Orleans, Louisiana. The American Heart Association’s Scientific Sessions bring together global experts to exchange the latest advancements in cardiovascular science, clinical care, and research. Thryv Therapeutics is honored to contribute to this important dialogue with its recent research highlighting the potential of SGK1 inhibition as a novel therapeutic strategy for cardiovascular disease, including heart failure. Dr. Rudolph currently serves as Head of Global Medical Affairs and Cross-TA Medical Affairs at Boehringer Ingelheim, where she leads a global transformation to build a market-leading Medical Affairs organization focused on external engagement, digital/AI integration, evidence generation, advanced analytics, and learning. “We are thrilled to welcome Amy Rudolph to our Board of Directors,” said Paul Truex, Chairman and CEO of Thryv Therapeutics. “Her extensive experience in medical affairs, evidence generation, and cross-functional drug development will be invaluable as we progress our SGK1 inhibitor pipeline toward late-stage clinical studies.” “We are also deeply grateful to Scott Weiner for his many contributions to the Board of Directors,” added Truex. “We’re pleased that he will remain closely involved with Thryv in an advisory capacity.” Prior to joining Boehringer Ingelheim, Dr. Rudolph held leadership roles at Novartis Pharmaceutical Corporation, where she served as Head of HCS (Healthcare Systems) Partnerships in Global Drug Development and Head of Evidence and Launch Excellence in Global Medical Affairs. Earlier in her career, she held key positions at Pfizer Inc., where she was responsible for the atherosclerosis and stroke platforms, early development, and licensing/technology evaluations, and began her scientific career with G.D. Searle/Pharmacia/Pfizer. Over the course of her career, Dr. Rudolph has played key roles in the development and launch of multiple cardiovascular therapies, including Inspra, Eliquis, Lipitor, Diovan, Diovan/HCT, Exforge, Tekturna, and Entresto, as well as in the development of Serelaxin and Amturnide. Dr. Rudolph earned her Ph.D. in Biochemistry and Molecular Biology from Washington University in St. Louis and is an inventor on 13 patents and numerous scientific publications spanning preclinical research, drug development, and real-world evidence. “I am honored to join Thryv Therapeutics’ Board of Directors,” said Amy Rudolph. “Thryv’s science and patient-centered mission resonate deeply with me, and I look forward to supporting the company’s continued progress in addressing serious cardiovascular conditions.” Dr. Rudolph joins the Board of Directors as Scott Weiner, who has served as a valued member since 2021, transitions to an observer role. Mr. Weiner will remain on the Board of Directors of the company’s subsidiary, Thryv Therapeutics USA, Inc., while also serving as an advisor to the company. About Thryv’s SGK1 Inhibitor Platform Thryv Therapeutics is advancing a portfolio of potent and selective SGK1 (serum and glucocorticoid-regulated kinase 1) inhibitors that target the fundamental mechanisms driving electrical and structural remodeling in the heart. THRV-1268, the company’s lead clinical candidate, is a best-in-class, highly selective SGK1 inhibitor with the potential to transform the treatment landscape for Long QT Syndrome (LQTS), heart failure (HF), and atrial fibrillation (AFib)—three serious cardiac conditions with urgent unmet medical needs. About Thryv Therapeutics Inc. Thryv Therapeutics Inc. is a privately owned company based in Montreal, Quebec, Canada. Thryv is pioneering a precision medicine approach to treat genetic channelopathies, cardiometabolic diseases, and cardiomyopathies with potent and highly selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). For more information, please visit www.thryvtrx.com. Media Inquiries brittany@thryvtrx.com | 514 973 0915

With new, positive data in hand, Merck & Co. plans to move its cardiovascular drug Winrevair into late-stage testing as a treatment for a condition often caused, at least in part, by high blood pressure.This condition known as heart failure with preserved ejection fraction, or HFpEF is common, affecting more than half of the roughly 6.7 million people in the U.S. believed to be living with heart failure. In these people, the hearts main pumping chamber stiffens over time due to a variety of possible factors, including age, obesity and hypertension. While the chamber still pumps a normal amount of blood, patients with HFpEF can experience fatigue, shortness of breath, as well as life-threatening health complications.The Food and Drug Administration has already approved several medicines for HFpEF, among them AstraZenecas Farxiga, Novartis Entresto, and Eli Lilly and Boehringer Ingelheims Jardiance. Merck has been trying to expand that list with Winrevair, a first-of-its-kind therapy that works by regulating signals from activin proteins that spur cell growth and division. In heart failure, the over-production of certain cells, molecules and proteins can harden the organ and impair its function.On Tuesday, Merck announced Winrevair had hit the main goal of a mid-stage clinical trial that enrolled 164 adults with high blood pressure in their pulmonary arteries caused by HFpEF. The study pitted two different doses of Winrevair against a placebo and, according to Merck, showed that about six months into treatment, the drug provided a significant and clinically meaningful improvement to blood flow through the lungs to the heart.In a statement, Mahesh Patel, vice president of global clinical development at Merck Research Laboratories, said these kinds of blood flow improvements could translate to better outcomes for this patient population.Merck didnt release any detailed data, but said it intends to present results at a future scientific meeting. In the meantime, its forging ahead into Phase 3 development.For Merck, which stands to lose patent protection on the worlds top-selling drug, Keytruda, in the not-too-distant future, the success of products like Winrevair is crucial. In 2024, Keytruda accounted for a little over half of the companys $57.4 billion in pharmaceutical sales.Merck picked up Winrevair through its $11.5 billion acquisition of Acceleron Pharma back in 2021. The drug is one of 20 growth drivers that, by Mercks estimates, could eventually make up for the expected declines to the Keytruda franchise. The company argues that almost all of these drivers have the potential to generate at least $1 billion in annual revenue and, collectively, their commercial opportunity exceeds $50 billion.Winrevair first received FDA approval in the spring of 2024, for a separate blood pressure disorder called pulmonary arterial hypertension. Sales of the drug totaled $976 million over the first nine months of this year.Carter Gould, an analyst at the investment firm Cantor Fitzgerald, wrote in a note to clients that this latest trial win should help Mercks stock price, especially since investors were ascribing value to Winrevair beyond PAH.Gould added that, among analysts, the average forecast has annual Winrevair sales peaking at $8 billion to $8.5 billion, with around $1 billion to $2 billion coming from outside of PAH, namely HFpEF.Merck shares were up more than 3%, to trade above $96 apiece, by late Tuesday morning. '